Abstract
Background: Mycetoma and chromoblastomycosis are both chronic subcutaneous infectious diseases that pose an obstacle to socioeconomic development. Besides the therapeutic issue, the diagnosis of most neglected tropical diseases (NTD) is challenging. Confirmation using direct microscopy and culture, recognized as WHO essential diagnostic tests, are limited to specialized facilities. In this context, there is a need for simple user-friendly diagnostic tests to be used in endemic villages. Methods: This review discuss the available biomarkers that could help to improve the diagnostic capacity for mycetoma and chromoblastomycosis in a theoretical and practical perspective. Results: A lack of research in this area has to be deplored, mainly for mycetoma. Biomarkers based on the immune response (pattern of leucocytes, antibody detection), the dermal involvement (extracellular matrix monitoring, protein expression), and the presence of the infectious agent (protein detection) are potential candidates for the detection or follow-up of infection. Conclusion: Confirmatory diagnosis based on specific diagnostic biomarkers will be the basis for the optimal treatment of mycetoma and chromoblastomycosis. It will be part of the global management of NTDs under the umbrella of stewardship activities.
Highlights
Mycetoma and chromoblastomycosis are both chronic subcutaneous infectious diseases that pose a devastating obstacle to public health, poverty reduction, and socioeconomic development
The authors suggested the possible role of macrophage inflammatory protein-1α (MIP-1α) in the fungi persistence during chromoblastomycosis and the regulatory role of macrophage activation in determining the outcome and fungal destruction in chromoblastomycosis infections. These results suggested the potential use of MIP-1α as a prognostic biomarker
This study demonstrates that chromoblastomycosis triggers autoreactivity against myeloid lysosomal antigens
Summary
Mycetoma and chromoblastomycosis are both chronic subcutaneous infectious diseases that pose a devastating obstacle to public health, poverty reduction, and socioeconomic development. For these reasons, they were formally recognized by the World Health Organization (WHO) as neglected tropical diseases (NTD) in 2016. Mycetoma and chromoblastomycosis are both chronic subcutaneous infectious diseases that pose an obstacle to socioeconomic development. Confirmation using direct microscopy and culture, recognized as WHO essential diagnostic tests, are limited to specialized facilities. In this context, there is a need for simple user-friendly diagnostic tests to be used in endemic villages. Methods: This review discuss the available biomarkers that could help to improve the diagnostic capacity for mycetoma and chromoblastomycosis in a theoretical and practical perspective
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
